GlaxoSmithKline : Q1 2022 results infographic PDF – 183.2KB – Marketscreener.com

GSK delivers strong Q1 2022 sales of £9.8 billion, +32% CER
Biopharma
£7.1bn + 40%
28.6%
Total Group operating margin
35.9p
+ 66%
Total EPS
£1.7bn
26.7%
Adjusted Group operating margin
32.8p
+ 43%
Adjusted EPS
14p
Free cash flow
Dividend
“We have delivered strong first quarter results in this landmark year for GSK, as we separate Consumer Healthcare and start a new period of sustained growth. Our results reflect further good momentum across specialty medicines and vaccines and continuing pipeline progress. We also continue to see very good momentum in Consumer Healthcare, demonstrating strong potential of this business ahead of its proposed demerger in July, to become Haleon.”
Emma Walmsley
CEO, GSK
All % at constant exchange rates (CER) Journalists/media see press release onwww.gsk.comfor full details on Q1 2022. Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures on pages 42 to 43 of the first quarter press release.
Attachments
Disclaimer
GSK – GlaxoSmithKline plc published this content on 27 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2022 06:24:05 UTC.

source